Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3924-3930

  Yusuf, Nabiha ^a,b   Nasti, Tahseen H ^a   Katiyar, Santosh K ^a   Jacobs, Michael K ^a   Seibert, Megan D ^a   Ginsburg, Alexis C ^a   Timares, Laura ^a,b   Xu, Hui ^a,b   Elmets, Craig A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; PHORBOL 13 ACETATE 12 MYRISTATE; CARCINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMICAL CARCINOGENESIS; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; WILD TYPE; ANIMAL; BONE MARROW CELL; C3H MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CONTACT DERMATITIS; DENDRITIC CELL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; SKIN TUMOR;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BONE MARROW CELLS; CARCINOGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DERMATITIS, CONTACT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON TYPE II; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SKIN NEOPLASMS;

EID: 45549109366     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3059     Document Type: Article

References (34)

1. Mukhtar H, Mercurio M, Agarwal R. Murine skin carcinogenesis: relevance to humans. In: Mukhtar H, editor. Skin cancer: mechanisms and human relevance. Boca Raton: CRC Press; 1995. p. 3-8.
2. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992;54:63-128.
3. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Haras during mouse skin carcinogenesis. Nature 1986;322: 78-80.
4. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci U S A 1990;87:538-42.
5. Bizub D, Wood AW, Skalka AM. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci U S A 1986;83:6048-52.
6. Pelling JC, Fischer SM, Neades R, Strawhecker J, Schweickert L. Elevated expression and point mutation of the Ha-ras proto-oncogene in mouse skin tumors promoted by benzoyl peroxide and other promoting agents. Carcinogenesis 1987;8:1481-4.
7. DiGiovanni J. Genetic factors controlling responsiveness to skin tumor promotion in mice. Prog Clin Biol Res 1995;391:195-212.
8. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995;1:1179-83.
9. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
10. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-9.
11. Girardi M, Glusac E, Filler RB, et al. The distinct contributions of murine T cell receptor (TCR){γ}{δ}+ and TCR{α}{β}+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003;198:747-55.
12. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003;197: 1017-28.
13. Anderson C, Hehr A, Robbins R, et al. Metabolic requirements for induction of contact hypersensitivity to immunotoxic polyaromatic hydrocarbons. J Immunol 1995;155:3530-7.
14. Klemme J, Mukhtar H, Elmets C. Induction of contact hypersensitivity to dimethylbenz[a]anthracene and benzo[a]pyrene in C3H/HeN mice. Cancer Res 1987;47: 6074-8.
15. Elmets C, Athar M, Tubesing K, Rothaupt D, Xu H, Mukhtar H. Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex. Proc Natl Acad Sci U S A 1998;95:14915-9.
16. Gould K, Dietrich W, Borenstein N, Lander E, Dove W. Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Genetics 1996;144:1769-76.
17. Marcela P, Su P, Ebeling C, et al. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet 1997;17:280-4.
18. Elmets CA, Zaidi SI, Bickers DR, M ukhtar H. Immunogenetic influences on the initiation stage of the cutaneous chemical carcinogenesis pathway. Cancer Res 1992;52:6106-9.
19. Xu H, DiIulio N, Fairchild R. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon γ-producing (Tc1) effector CD8+ T cells and interleukin (IL) 4/IL-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996;183:1001-12.
20. Yusuf N, Nasti TH, Long JA, et al. Protective Role of Toll-like Receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008; 68:615-22.
21. He D, Wu L, Kim HK, Li H, Elmets CA, Xu H. CD8+ IL-17-producing T Cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006;177:6852-8.
22. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
23. Dunn GP, Old LJ, Schreiber RD. The Three Es of cancer immunoediting. Annu Rev Immunol 2004;22: 329-60.
24. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002;71:1-8.
25. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76.
26. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-[β] induces development of the TH17 lineage. Nature 2006;441:231-4.
27. Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-21.
28. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40.
29. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177: 566-73.
30. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177-89.
31. Honorati MC, Neri S, Cattini L, Facchini, A. IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 2003;133:344-9.
32. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7.
33. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114-21.
34. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-704.